OpenAI on April 16 introduced GPT-Rosalind, a frontier reasoning model built for drug discovery, genomics analysis, protein reasoning and other scientific research tasks. The release expands OpenAI’s push beyond general-purpose assistants into specialized workflows where long-context reasoning, data handling and domain-specific analysis can carry direct commercial and research value.